Targeting both isoforms of PI3K in combination with a PD-L1 blocking antibody delayed tumor growth and prolonged survival in tumor models of head and neck cancer, indicating a beneficial effect of this treatment combination (83). The gene discussed is PIK3CA; the disease is neoplasm.